Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.925 SEK | 0.00% | -6.94% | +34.25% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+34.25% | 63.95M | C+ | ||
+2.53% | 42.75B | B | ||
+47.70% | 41.61B | A | ||
+12.07% | 41.34B | B- | ||
-8.83% | 26.59B | C | ||
+6.91% | 25.49B | B- | ||
-22.83% | 18.12B | B | ||
+30.49% | 12.24B | C+ | ||
-2.05% | 11.76B | C+ | ||
+9.17% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ATORX Stock
- Ratings Alligator Bioscience AB